Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228891 · ClinicalTrials.gov registry record · Phase 2
Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus
A Phase 2 study, sponsored by Florida Atlantic University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00228891 is a Phase 2 study that was terminated before completion, run by Florida Atlantic University. The registered enrollment target is 152 participants.
The verdict
NCT00228891, a Phase 2 study, was terminated before completion, sponsored by Florida Atlantic University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
Diabetic neuropathy is a progressive complication causing serious problems in 25-40% of diabetic patients. Anecdotal reports have indicated improvement with pulsatile IV insulin in patients otherwise resistant to all conventional therapies. Significant complications produce painful peripheral dysesthesias, loss of sensation and gastroparesis. This study is designed to test the effectiveness of pulsatile insulin delivery on diabetic neuropathy.
Interventions
- PROCEDURE Effect of Pulsatile IV insulin on diabetic neuropathy
- PROCEDURE Effect of Pulsatile IV Insulin on diabetic neuropathy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228891
The ClinicalTrials.gov registry entry for NCT00228891 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Florida Atlantic University, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Effect of Pulsatile IV insulin on diabetic neuropathy is the first listed.
NCT00228891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00228891 about?
NCT00228891 is a clinical study titled "Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus". Diabetic neuropathy is a progressive complication causing serious problems in 25-40% of diabetic patients. Anecdotal reports have indicated improvement with pulsatile IV insulin in patients otherwise resistant to all conventional therapies. Significant complications produce painful peripheral dysest...
What is the current status of trial NCT00228891?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2004-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00228891?
The interventions under investigation include: Effect of Pulsatile IV insulin on diabetic neuropathy (PROCEDURE), Effect of Pulsatile IV Insulin on diabetic neuropathy (PROCEDURE).
Who is sponsoring clinical trial NCT00228891?
This trial is sponsored by Florida Atlantic University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.